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Abstract
Background: Nonmelanoma skin cancer is the most prevalent post-transplant malignancy found in renal
transplant recipients. Long term immunosuppressant therapy, previous history of nonmelanoma skin cancer
and UV exposure are the greatest drivers of these malignancies in renal transplant recipients compared to the
general population. Squamous cell carcinoma is the most prevalent type of nonmelanoma skin cancer lesions
that can lead to increased morbidity and metastasis in this population. Sirolimus is a relatively new
immunosuppressant that is known to have anti-tumor effects, especially in the instance of skin cancer. Will
sirolimus reduce the recurrence of nonmelanoma skin cancer in renal transplant recipients with a previous
history of nomelanoma skin cancer?
Method: An extensive medical literature search was completed using MEDLINE, CINAHL, EBSCO, and
Web of Knowledge. Search terms used included skin cancer, skin neoplasm, organ transplant, renal transplant,
and sirolimus. Relevant articles were further evaluated for quality using the GRADE criteria.
Results: Three randomized controlled trials met the inclusion criteria of the systematic review. The studies
showed a decreased incidence of nonmelanoma skin cancer in renal transplant recipients with a history of
nonmelanoma skin cancer. One study demonstrated a significantly longer survival free of squamous cell
carcinoma in the sirolimus group compared to calcineurin inhibitor therapy. Another study found a
significantly decreased rate of nonmelanoma skin cancer in the sirolimus group. All studies observed an
increased incidence of adverse drug reactions in the sirolimus group that led to high discontinuation rates. The
overall quality of evidence was low after assessing each study with GRADE criteria.
Conclusion: The findings suggest that sirolimus is effective at reducing the recurrence of nonmelanoma skin
cancer lesions in renal transplant recipients with a history of nonmelanoma skin cancer. While there appears
to be some significance for sirolimus conversion of renal transplant recipients with nonmelanoma skin cancer,
better quality research is necessary to determine the long term effects of sirolimus in renal transplant patients.
Further studies are needed to determine when sirolimus should be initiated in patients to prevent skin cancer
and treatment duration.
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Abstract   
 
Background: Nonmelanoma skin cancer is the most prevalent post-transplant malignancy found 
in renal transplant recipients. Long term immunosuppressant therapy, previous history of 
nonmelanoma skin cancer and UV exposure are the greatest drivers of these malignancies in renal 
transplant recipients compared to the general population. Squamous cell carcinoma is the most 
prevalent type of nonmelanoma skin cancer lesions that can lead to increased morbidity and 
metastasis in this population. Sirolimus is a relatively new immunosuppressant that is known to 
have anti-tumor effects, especially in the instance of skin cancer. Will sirolimus reduce the 
recurrence of nonmelanoma skin cancer in renal transplant recipients with a previous history of 
nomelanoma skin cancer?  
Method: An extensive medical literature search was completed using MEDLINE, CINAHL, 
EBSCO, and Web of Knowledge. Search terms used included skin cancer, skin neoplasm, organ 
transplant, renal transplant, and sirolimus. Relevant articles were further evaluated for quality 
using the GRADE criteria. 
Results: Three randomized controlled trials met the inclusion criteria of the systematic review. 
The studies showed a decreased incidence of nonmelanoma skin cancer in renal transplant 
recipients with a history of nonmelanoma skin cancer. One study demonstrated a significantly 
longer survival free of squamous cell carcinoma in the sirolimus group compared to calcineurin 
inhibitor therapy. Another study found a significantly decreased rate of nonmelanoma skin cancer 
in the sirolimus group. All studies observed an increased incidence of adverse drug reactions in 
the sirolimus group that led to high discontinuation rates. The overall quality of evidence was low 
after assessing each study with GRADE criteria. 
Conclusion: The findings suggest that sirolimus is effective at reducing the recurrence of 
nonmelanoma skin cancer lesions in renal transplant recipients with a history of nonmelanoma 
skin cancer. While there appears to be some significance for sirolimus conversion of renal 
transplant recipients with nonmelanoma skin cancer, better quality research is necessary to 
determine the long term effects of sirolimus in renal transplant patients. Further studies are 
needed to determine when sirolimus should be initiated in patients to prevent skin cancer and 
treatment duration. 
 
Keywords: Sirolimus, renal transplant recipients, skin cancer, skin neoplasm
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The use of Sirolimus as Secondary Prevention in Nonmelanoma Skin Cancer in 
Renal Transplant Recipients 
BACKGROUND 
 In 2010, there were 16 843 kidney transplants in the United States for patients age 
20 years and older.1 Advances in immunosuppressant therapy have improved organ 
transplant outcomes. Graft failure rates are at an all-time low and long term survival of 
kidney transplant recipients is increasing.1 Consequently, physicians have witnessed 
more long term complications, such as post-transplant malignancies.2 The most common 
type of post-transplant malignancy seen in renal transplant recipients is nonmelanoma 
skin cancer (NMSC).2,3 Nonmelanoma skin cancer, with squamous cell carcinoma (SCC) 
being the most prevalent, accounts for 95% of skin cancer found in organ transplant 
patients.4 One German study5 found a 20-fold increase in the incidence of nonmelanoma 
skin cancers among renal transplant recipients. Investigators have found that these skin 
cancers are more worrisome due to their increased incidence of recurrence and metastasis 
in renal transplant recipients.6  
 The greatest drivers in the incidence of SCC lesions among this population are 
immunosuppressant therapy and UV exposure.7 Age, UV exposure, previous history of 
NMSC, history of sunburn, and skin type have been identified as predictive factors for 
NMSC in renal transplant recipients.8 Primary immunosuppressive prophylaxis includes 
calcineurin inhibitors (CNIs), mycophenolates, azathioprine, corticosteroids, mammalian 
target rapamycin inhibitors, and IL-2 receptor antibodies.9 
Calcineurin inhibitors, such as cyclosporine and tacrolimus, have had an impact 
on the improved outcomes of organ transplant recipients.10 CNIs inhibit cytokine 
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production by binding to intracellular mediators and blocking T cell signals.8 Also, CNIs 
inhibit mitochondrial permeability transition pore (MPTP) channels, which are 
responsible for cell death.3 In cyclosporine treated mice7,10, cyclosporine demonstrated an 
enhanced effect of tumor growth. Azathioprine and UVA light react together to form 
mutagenic metabolites that enhance photosensitivity of the skin.3,7 This enables UVA 
light to directly damage DNA, which in combination with photosensitivity, increases the 
incidence of SCC.7  
 In 2008, the FDA approved a new immunosuppressant, sirolimus, for prophylaxis 
for renal transplant recipients. Sirolimus is a mammalian target of rapamycin (mTOR) 
inhibitor. Mammalian target of rapamycin is a protein that regulates cell growth, cell 
proliferation, cell motility, cell survival, protein synthesis, and transcription. Sirolimus 
acts to inhibit IL-2 mediated signal transduction to stop the proliferation of T cells and B 
cells. In contrast to cyclosporine, sirolimus inhibits the growth of malignant cells and has 
demonstrated reduced tumor growth.7,11 Studies11,12  have found that renal transplant 
recipients who converted to sirolimus therapy had a significantly reduced  incidence of 
malignancy compared to other immunosuppressants. Among renal transplant recipients 
with a history of NMSC, is sirolimus effective in reducing the recurrence of 
nonmelanoma skin cancer?  
METHODS 
An extensive medical literature search was completed using MEDLINE, 
CINAHL, Evidence Based Medicine Review Multifile, and Web of Knowledge. Search 
terms used included skin cancer, skin neoplasm, organ transplant, renal transplant, and 
sirolimus. Inclusion criteria consisted of randomized control trials with renal transplant 
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recipients with a previous history of NMSC lesions, use of sirolimus as 
immunosuppressant therapy, and articles written in English. Studies that consisted of 
combination therapy with sirolimus and another immunosuppressant, other solid organ 
transplant recipients, and patients without a previous history of NMSC were excluded 
from the study. Relevant articles were further evaluated for quality using the GRADE 
criteria.13 
RESULTS 
 The literature search yielded 25 studies for review. After screening for relevant 
articles, 15 non-relevant articles were excluded. Three studies14-16 met the inclusion 
criteria and were incorporated into the systematic review.  All studies were randomized 
control trials (RCTs).  
Euvrard et al study 
 This multicenter, randomized, open label trial14 investigated the efficacy of 
sirolimus in secondary prevention of skin cancer in renal transplant recipients. The study 
enrolled and randomized 129 patients and 120 patients were included in the primary 
analysis. Eligibility criteria included renal transplant recipients with stable graft function, 
a post-transplant history of SCC, and who are currently receiving CNI treatment. There 
were 64 patients assigned to the sirolimus group and 56 patients in the calcineurin 
inhibitor group. Patients were randomly assigned to continue receiving CNI therapy or to 
transition from CNI to sirolimus therapy. In the sirolimus group, CNI therapy was 
discontinued and sirolimus was added until blood concentrations of sirolimus reached 6 
to 12ng per milliliter. Sirolimus conversion therapy was considered rapid if CNI was 
discontinued within 7 days and progressive if CNI was discontinued beyond 7 days. 
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Exclusion criteria included multiorgan transplants, patients with in situ lesions, graft 
rejection in the past 6 months, poor graft function, uncontrolled hyperlipidemia, 
hematologic or hepatic disorders, and retinoid treatment.14 
The primary outcome was survival, free of SCC at 2 years. Secondary outcomes 
included time until the development of new SCC, development of other skin cancer, graft 
function, and adverse drug events (ADRs) to sirolimus. Patients were examined by a 
nephrologist and dermatologist initially, and then every 3 months for 2 years. The 
dermatology examination included Fitzpatrick’s classification of skin type, sun exposure, 
and number of lesions before and after randomization. The nephrologist monitored the 
immunosuppressant dosage of each patient at their visit. The sirolimus group was 
monitored weekly for the first 2 weeks, monthly for the first 2 months, and every 3 
months for the next 2 years.14 
Baseline characteristics were balanced between the two study groups. At baseline, 
120 patients were diagnosed with SCC, of which 55% had a single lesion, and 45% had 
multiple lesions. Calcineurin inhibitor therapy included 84 patients on cyclosporine and 
36 patients receiving tacrolimus.14  
The study determined the survival free of SCC, was significantly longer with 
sirolimus therapy compared to the CNI group (hazard ratio 0.37, 95% CI 0.16 to 0.85). 
This was significant for patients with a single SCC (hazard ratio 0.03, 95% CI 0.0 to 
0.91), but not for those with multiple SCC (hazard ratio 0.67, 95% CI 0.29 to 1.54). 
Development of new SCC occurred in 14 patients in the sirolimus group and 22 patients 
in the CNI group (RR= 0.56, 95% CI 0.32 to 0.98). In the sirolimus group, 6 patients 
developed new SCC after sirolimus withdrawl.14 
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 The study found that more sirolimus patients experienced an ADR (60 serious 
adverse events vs 14 adverse events in the CNI group). Adverse drug events occurred in 
37 out of 64 patients in the sirolimus group. This was more likely to occur with those 
patients who underwent rapid conversion compared to progressive conversion from CNI 
to sirolimus. Also, those who underwent rapid conversion had a higher discontinuation 
rate. The study decreased the sirolimus dose, which controlled most of the ADRs, but 15 
patients (23%) discontinued after a median of 2.5 months. Some of the ADRs observed 
included edema, acne like lesions, aphthous ulcers, and proteinuria.14 
 The study concluded that switching to sirolimus from CNI decreased the risk and 
rate of SCC lesions. Because the study was inadequately powered, there were no 
significant differences between the groups concerning the rate of SCC. The authors 
suggest that early conversion to sirolimus is more efficacious for patients with newly 
diagnosed SCC.14 
Campbell et al study 
 This prospective, multicenter, open label, randomized control trial15 compared the 
rate and occurrence of NMSC in stable renal transplant patients who converted to 
sirolimus treatment to those currently on CNI therapy. The study was conducted in 
Australia, New Zealand, and the United States and was sponsored by Pfizer 
Pharmaceuticals. The primary outcome was the number of biopsies confirmed; NMSC 
lesions that occurred within the study duration of 1 year plus 1 month for follow up. The 
secondary outcomes included the rate for the first new NMSC lesion to occur.15 
Patients who were renal transplant recipients within at least 1 year, 18 years or 
older, who are currently on CNI, and have a history of NMSC within the past 3 years, 
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were included in the study. The authors excluded those with unstable graft function, and 
other malignancies besides NMSC. Those receiving treatment for their skin lesions, such 
as retinoid treatment, phototherapy, topical agents, chemical peels, and laser treatments, 
were excluded from the study.15 
 Patients were stratified by the number of NMSC lesions within the last 1 year and 
then randomly assigned to sirolimus conversion or continuing calcineurin inhibitors. 
They were assigned to study groups using a computer generated program, Clinical 
Operation Randomization Environment. Those converting to sirolimus discontinued their 
CNI and were dosed accordingly until whole blood trough concentrations of 5ng/mL 
were maintained.15 
 Baseline characteristics were similar between the study groups. From Sept 2005 
to Oct 2007, eighty seven patients were enrolled and randomized. One patient was 
randomized in error. With 86 patients included in the trial, 39 patients were assigned to 
convert to sirolimus and 47 patients continued CNI therapy. Initially, follow up was to 
consist of a 2 year study duration plus 1 month follow up, but due to low enrollment and 
high discontinuation rate, follow up was reduced to 1 year study duration plus 1 month 
follow up. The most common reason for discontinuation in the sirolimus group was 
adverse drug reactions.15  
 The study found that the sirolimus group had a significantly lower yearly rate of 
new biopsy confirmed NMSC lesions compared to the CNI group (1.31 vs 2.48, 
p=0.022).14 Fewer patients developed new or recurrent NMSC lesions in the sirolimus 
group compared to the CNI group (56.4% vs 80.9%, RR= 0.07; p= 0.015) and new SCC 
(41.0% vs 70.2%, RR= 0.58; p= 0.006).15 The study15 found no significant difference 
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between groups concerning the incidence of any serious ADRs (sirolimus 38.5% vs CNI 
44.7%, RR=0.86). Eighteen patients in the sirolimus group discontinued their assigned 
treatment due to adverse drug reactions. The most frequent ADRs observed were 
pneumonitis, diarrhea, and decreased tolerance.15 
 The authors concluded that switching to sirolimus lowered the amount of NMSC 
lesions that occurred in renal transplant recipients. The study was limited due to the high 
discontinuation rate in the sirolimus group. Factors that may have contributed to this 
include abrupt conversion to sirolimus from CNI, higher loading doses and blood 
concentrations higher than what is used in current practice, and patient related factors.15 
The authors noted that the overall rate reduction of NMSC lesions was driven by lower 
SCC rates compared to BCC rates, but the study did not calculate a difference between 
these two lesions. Also, the authors speculate that CNI withdrawl after converting to 
sirolimus may have contributed to the decrease in the yearly incidence of NMSC lesions. 
CNIs and other immunosuppressants are thought to enhance tumor growth, while 
sirolimus interferes with angiogenesis and cancer cell growth.15 
Salgo et al study 
 This is a single center, prospective, single blinded randomized control trial16 that 
assessed whether switching to sirolimus decreased the progression of malignancies and 
the number of new NMSC lesions that occurred compared to other immunosuppressants. 
There were 44 patients enrolled in the study and randomly assigned to treatment groups. 
Patients were included in the study if they had stable renal function, were between 18 and 
75 years, have a history of NMSC, actinic keratosis, verruca vulgaris, and had renal 
transplantation for more than 1 year. Those who underwent previous sirolimus therapy, 
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were pregnant or planning for pregnancy, and had hematologic disorders were excluded 
from the study. Patients were seen a dermatologist, who was blinded to treatment groups 
throughout the study. Dermatology visits occurred at baseline, 6 months, and 12 months, 
and involved the same dermatologist.16  
 Both study groups had similar baseline characteristics. There were 25 patients 
converted to sirolimus and 19 patients continuing their original immunosuppressant 
therapy. The study duration was 12 months.16  
 The secondary outcome the occurrence of new NMSC lesions within the 1 year 
study duration. Focus was placed on the secondary outcome due to its relevance to the 
clinical question. Development of new NMSC lesions occurred in 1 patient in the 
sirolimus group and 8 patients in the control group. The most common ADRs that 
occurred were aphthous ulcers, leg edema, and diarrhea.16 Also, ADRs were observed 
between treatment groups. In the sirolimus group, 7 patients were lost to follow up due to 
ADRs compared to 1 patient in the control group.16 
 The authors noted the limitations to their study including small sample size (n= 
33) and the short study duration or 1 year.16 Also, the authors acknowledged that the high 
dropout rate in the sirolimus group was a weakness of the study. It is also speculated that 
those on azathioprine who converted to sirolimus may have seen a benefit due to the 
discontinuation of azathioprine rather than the initiation of sirolimus. The study 
concludes that sirolimus may be an option for renal transplant recipients with a history of 
NMSC, but larger multicenter studies are needed for further investigation.16 
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DISCUSSION 
 Renal transplant recipients have an increased incidence in post-transplant 
recipients, such as nonmelanoma skin cancer. Due to the anti-tumor effects of sirolimus, 
this may prove to be a valuable option as secondary prevention for renal transplant 
recipients with a history of NMSC. The above three studies14-16 demonstrated that a 
conversion to sirolimus reduced the incidence of NMSC in renal transplant patients with 
a history of NMSC. Furthermore, all studies14-16 were randomized control trials that 
demonstrated a reduced incidence of SCC lesions within the sirolimus treatment group. 
Sirolimus conversion led to a significantly lower rate of new NMSC lesions per patient 
year compared to the CNI group.14 Those patients who converted to sirolimus appeared to 
be survival free of SCC lesions significantly longer than those in the CNI group.14 
Euvrard et al14 and Salgo et al16 observed an increased incidence of ADRs in the 
sirolimus group, while Campbell et al15 did not observe a significant difference in the 
incidence of ADRs between study groups. However, in Campbell et al15, ADRs were the 
leading cause of discontinuation from the sirolimus group. This may be due to the 
difference in sirolimus conversion protocols between the studies.14-16  
While the evidence supports sirolimus conversion for immunosuppressive 
treatment in renal transplant recipients with a history of NMSC, there were limitations to 
these studies. Two studies14,15 lacked group allocation concealment and were open label 
studies, indicating that they were not blinded. The articles15,16  lacked precision due to 
lack of confidence intervals and use of p values for significance.  Two studies14,15 
demonstrated a high discontinuation rate in the sirolimus group due to adverse drug 
reactions. This resulted in small study populations and shortened study durations.14,15 For 
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example, Campbell et al15 calculated a sample size of 180 patients was needed for 90% 
power, but due to high discontinuation rates and low patient enrollment, only 86 patients 
were included in the study.  
 The quality of the data was further compromised with publication bias. Campbell 
et al15 demonstrated publication bias in their study. The study was sponsored by Wyeth 
Pharmaceuticals, a subsidiary of Pfizer Inc., who manufacture sirolimus. In Euvrard et 
al14, Pfizer provided a research grant, but the study denies Pfizer having a role in the trial 
design or the collection and interpretation of data, which makes publication bias unlikely.  
 The overall quality of evidence using GRADE criteria13 was low. Due to reasons 
discussed above, Campbell et al15 was downgraded to very low quality. Two studies14,16 
were downgraded to low quality. This includes Salgo et al16, which was downgraded due 
to lack of precision and only utilizing secondary outcomes relevant to the clinical 
question. 
 Currently, more research is being conducted to further investigate the effects of 
sirolimus on NMSC in renal transplant recipients. More research is needed to determine 
if the beneficial effect of the conversion to sirolimus is due to sirolimus’ mechanism of 
action or to the discontinuation of the other immunosuppressant.16 The TUMORAPA 
study17 is an ongoing study comparing sirolimus conversion to CNIs in renal transplant 
recipients with SCC over a 5 year period. Further studies are needed to determine when 
sirolimus should be initiated in patients to prevent skin cancer and what the treatment 
duration should be. More research is needed to determine the cost effectiveness of 
sirolimus compared to other immunosuppressive therapy. Also, further studies 
investigating the long term treatment effects of sirolimus on mortality are needed. 
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CONCLUSION 
 Sirolimus was demonstrated to be efficacious in reducing the incidence of NMSC 
lesions in renal transplant recipients with a history of NMSC. While it appears that 
sirolimus has an integral role in secondary prevention of NMSC, the treatment does not 
appear to be well tolerated and has serious adverse drug events. Sirolimus is a valuable 
treatment option for renal transplant recipients with a history of NMSC, but it is not 
likely that sirolimus will replace standard immunosuppressive regimens, such as 
cyclosporine. Further research is needed to demonstrate the long term effects of sirolimus 
and its safety in renal transplant recipients. 
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Table 1: GRADE Evidence Profile 
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aLack of blinding, lack of allocation concealment, and follow up was amended due to low enrollment and high discontinuation rates. 
bCampbell et al study1 was designed to have approximately 90% power with a sample size of 90 patients per study group. However, only a total of 86 patients were included in the study. The use of p values rather than confidence intervals for statistical 
significance contributed to the lack of imprecision. 
cCampbell et al study1 was sponsored by Pfizer  
dYearly NMSC rate per patient year.  
eEuvrard et al study2 lacked blinding and group allocation was not concealed.  
fEuvrard et al study2 had a small study population with a total of 120 patients. Also, 95% CI (0.32-0.98) demonstrates a wide confidence interval and decreased precision.  
gLack of blinding, lack of allocation concealment, and follow up was amended due to low enrollment and high discontinuation rate in the Campbell et al study1 and Euvrard et al study2. 
hSalgo et al study3  was downgraded due to having only the secondary outcome having relevance to the clinical question.  
iSmall sample sizes demonstrated a lack of precision in all studies1-3.Campbell et al study1 lacked confidence intervals and Euvrard et al study2 had wide confidence intervals, which demonstrated a further lack of precision.
Quality Assessment Summary of Findings 
Importance  Downgrade Criteria  Number of Patients Effect 
Quality No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely Study 
Treatment 
(total) 
Placebo or 
no treatment 
(total) 
Relative 
Risk NNT/NNH 
Outcome #1: Decreased rate of NMSC lesions 
1 
 
RCT 
 
Very 
Serious 
limitationsa 
No serious 
indirectness 
Very serious 
imprecisionb 
No serious 
inconsistencies 
Bias very 
likelyc 
Campbell et al1 1.31d 2.48d - - Very low Critical 
Outcome #2: Survival free of squamous cell carcinoma 
1 RCT  
Serious 
limitationse 
No serious 
indirectness 
Serious 
imprecisionf 
No serious 
inconsistencies 
Bias not 
likely Euvrard et al
2 14/64 22/56 0.56 6 Low Critical 
Outcome #3: Development of new NMSC lesions 
3 RCT  
Very 
Serious 
limitationsg 
Serious 
indirectnessh 
Serious 
imprecisioni 
No serious 
inconsistencies 
Bias very 
likelyc 
Campbell et al1 56.4% 80.9% 0.7 4 
Low Critical Euvrard et al2 14/64 22/56 0.56 6 
Salgo et al3 1/25 8/19 0.09 3 
Outcome #4: Adverse reactions to Sirolimus 
2 RCT  
Very 
serious 
limitations 
No serious 
indirectness 
Serious 
imprecision 
No serious 
inconsistencies 
Bias very 
likelyc 
Campbell et al1 38.5% 44.7% 0.86 16 
Low Important 
Euvrard et al2 37/64 14/56 2.28 3 
Salgo et al3 7/25 1/19 5.38 5 
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